BiotechTube

Lebrikizumab

ApprovedRecruiting
2 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

Jun 16, 2025 → Sep 1, 2026

NCT ID
NCT07006792

About Lebrikizumab

Lebrikizumab is a approved stage product being developed by Eli Lilly for Atopic Dermatitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07006792. Target conditions include Atopic Dermatitis.

What happened to similar drugs?

20 of 20 similar drugs in Atopic Dermatitis were approved

Approved (20) Terminated (1) Active (0)
✅tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅tacrolimusAstellas PharmaApproved
✅tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
✅Tacrolimus 0.03% + Fluticasone 0.005%Astellas PharmaApproved
✅Protopic + Corticosteroid + placeboAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (9)

NCT IDPhaseStatus
NCT07006792ApprovedRecruiting
NCT05372419Phase 3Completed
NCT05369403Phase 3Completed
NCT04840901Phase 1Completed
NCT04392154Phase 3Completed
NCT04250350Phase 3Completed
NCT04250337Phase 3Completed
NCT04178967Phase 3Completed
NCT04146363Phase 3Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
40
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
40
LebrikizumabEli LillyPhase 3
40
Lebrikizumab + PlaceboEli LillyPhase 3
44
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
19
LebrikizumabEli LillyPhase 3
40
ASN008Formation BioPhase 2
25
ENS-002Concerto BiosciencesPhase 1
11
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
35
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
YH35324 + Placebo + OmalizumabYuhanPhase 1
29
DS-2741a + PlaceboDaiichi SankyoPhase 1
21
SUN13834 + PlaceboDaiichi SankyoPhase 2
35
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
35
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
35
tacrolimus ointmentAstellas PharmaPhase 3
40
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
43
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
43
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaApproved
43